¼¼°èÀÇ ÀڱðæºÎ¾Ï Áø´Ü ½ÃÀå º¸°í¼­ : °Ë»ç À¯Çü, ¿¬·ÉÃþ, Áö¿ªº°(2025-2033³â)
Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2025-2033
»óǰÄÚµå : 1820203
¸®¼­Ä¡»ç : IMARC
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 140 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,313,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ® µîÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,751,000
PDF & Excel (5 User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ Copy&Paste°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. Àμâ´Â 5ºÎ±îÁö °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,190,000
PDF & Excel (Corporate License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ Copy&Paste°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. Àμâ´Â 5ºÎ±îÁö °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÀڱðæºÎ¾Ï Áø´Ü ½ÃÀå ±Ô¸ð´Â 2024³â 83¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 127¾ï ´Þ·¯¿¡ À̸£¸ç 2025-2033³â CAGRÀº 4.56%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÀڱðæºÎ¾Ï Áø´ÜÀº ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º(HPV)ÀÇ ºñÁ¤»óÀûÀÎ ¼¼Æ÷¿Í ±ÕÁÖ¸¦ Æò°¡Çϱâ À§ÇÑ ÀÏ·ÃÀÇ °í±Þ ½ÇÇè½Ç °Ë»ç, µµ±¸ ¹× ÀýÂ÷¿¡ ÀÇÁ¸ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â ¿øÃß ÀýÁ¦, ÆÝÄ¡ »ý°Ë, Àڱà °æºÎ ³»¸· ¼ÒÆÄ¼ú, Áú°æ°Ë»ç ½Ã Àڱà °æºÎÀÇ Á¤¹Ð °Ë»ç¸¦ À§ÇÑ Àü¼± ·çÇÁ¿¡ ÀÇÇØ ¾òÀº Á¶Á÷ »ùÇÃÀ» äÃëÇÏ¿© ¼öÇàµË´Ï´Ù. ¹ß°ß ÈÄ´Â Ç÷¾× °Ë»ç, ÈäºÎ X¼± °Ë»ç, CT °Ë»ç, MRI °Ë»ç, PET °Ë»ç, ¹æ±¤À̳ª Á÷ÀåÀÇ ½ÃÃËÁø µîÀ» ½Ç½ÃÇÏ¿© º´±â¸¦ ÆÇÁ¤ÇÕ´Ï´Ù.

¸Åµ¶, Ŭ¶ó¹Ìµð¾Æ, ÀÓº´, ÈÄõ¼º ¸é¿ª °áÇÌ ÁõÈıº(HIV/AIDS) µî ¼ºÇàÀ§ °¨¿°Áõ(STI)À¸·Î Áø´ÜµÇ´Â ȯÀÚ ¼ö°¡ ´ëÆø Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ¼¼°èÀûÀ¸·Î HPV °¨¿°ÀÇ À§ÇèÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. À̰ÍÀº Àڱà °æºÎ¾ÏÀ» °³¹ßÇÒ °¡´É¼ºÀ» ³ôÀÌ´Â Èí¿¬ÀÚ Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½Å¼ÓÇϰí Á¤È®ÇÑ °Ë»ç °á°ú¸¦ Á¦°øÇÏ´Â HPV °¡Á¤¿ë °Ë»ç ŰƮÀÇ Ã¤ÅÃÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. À¯¸®ÇÑ »óȯ Á¤Ã¥ÀÇ Á¸Àçµµ ½ÃÀå ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù. À̿ʹ º°µµ·Î, ¸ÂÃã Ä¡·á°èȹ¿¡ ´ëÇÑ ±âÈ£ÀÇ °íÁ¶°¡ ÀڱðæºÎ¾Ï Áø´Ü ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, È­ÇÐ ¿ä¹ý, ¿Á¼ö¼ö »ý°Ë, ¸é¿ª ¿ä¹ý, ±â°ü ÀýÁ¦¼ú µî ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀ» »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â Á¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. °Ô´Ù°¡ Àúºñ¿ëÀ¸·Î È¿À²ÀûÀÎ °Ë»ç Á¦Ç°ÀÇ °³¹ßÀÌ Á߽õǰí ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ÀڱðæºÎ¾Ï Áø´Ü ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : °Ë»ç À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦9Àå SWOT ºÐ¼®

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global cervical cancer diagnostics market size reached USD 8.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.56% during 2025-2033.

Cervical cancer diagnostics rely on a series of advanced laboratory tests, tools and procedures to evaluate abnormal cells or strains of the human papillomavirus (HPV). They are performed by taking a sample of the tissue obtained through conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. After detection, tests like blood, chest X-ray, body computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and visual examination of bladder and rectum are conducted to determine the disease stage.

A considerable rise in the number of individuals diagnosed with sexually transmitted infections (STIs), such as syphilis, chlamydia, gonorrhea and acquired immune deficiency syndrome (HIV/AIDS), is escalating the risk of HPV infection worldwide. This, along with the growing number of smokers, which increases the chances of developing cervical cancer, represents one of the key factors bolstering the market growth. Furthermore, the rising awareness about early diagnosis is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. The presence of favorable reimbursement policies also supports the market growth. Apart from this, rising preferences for personalized treatment plans are escalating the demand for cervical cancer diagnostics. Additionally, the availability of a range of other treatment options, including surgery, radiation therapy, chemotherapy, cone biopsy, immunotherapy and trachelectomy, is contributing to the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.

Key Market Segmentation:

Breakup by Test Type:

Breakup by Age Group:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cervical Cancer Diagnostics Market

6 Market Breakup by Test Type

7 Market Breakup by Age Group

8 Market Breakup by Region

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â